Abstract
With the discovery of antimicrobials and their insertion in the clinic, microorganisms quickly began to develop resistance mechanisms, causing significant morbidity and mortality, especially in immunocompromised patients, in addition to higher costs for health systems. The situation becomes even more critical due to the fact that there are few antifungal drugs available on the market and …